OncoMatch/Clinical Trials/NCT03778814
TCR-T Cell Immunotherapy of Lung Cancer and Other Solid Tumors
Is NCT03778814 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies TCR-T cells for nonsmall cell lung cancer.
Treatment: TCR-T cells — Tumor organoids and TILs (and/or peripheral T cells) cultures will be established from fresh tissure of lung cancer and other solid tumors. Coculture will be utilized to screen tumor-responsive T cells which are further selected for monoclonal expansion and TCR cloning for engineered reconstitution of TCR-T cells. After verification by multiple in vitro and in vivo studies, a large number of TCR-T cells will be introduced back into the patients via vein, artery or fine needle punctured to the tumor, or combinations. In this phase I study, the safety, tolerance and preliminary efficacy of the TCR-T cell immunotherapy on human will firstly be assessed.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Non-Small Cell Lung Carcinoma
Tumor Agnostic
Demographics
Prior therapy
Cannot have received: gene therapy
Lab requirements
Kidney function
adequate kidney function
Liver function
Child-Pugh-Turcotte score <7; adequate liver function
Cardiac function
adequate heart function
Child-Pugh-Turcotte score <7; Adequate heart,lung,liver,kidney function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT03778814 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior gene therapy disqualifies patients from enrollment.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages